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Abstract
Objective
To study the genetic and phenotypic spectrum of patients harboring recessive mutations in
BVES.
Methods
We performed whole-exome sequencing in a multicenter cohort of 1929 patients with a sus-
pected hereditary myopathy, showing unexplained limb-girdle muscular weakness and/or el-
evated creatine kinase levels. Immunohistochemistry and mRNA experiments on patients’
skeletal muscle tissue were performed to study the pathogenicity of identiﬁed loss-of-function
(LOF) variants in BVES.
Results
We identiﬁed 4 individuals from 3 families harboring homozygous LOF variants in BVES, the
gene that encodes for Popeye domain containing protein 1 (POPDC1). Patients showed
skeletal muscle involvement and cardiac conduction abnormalities of varying nature and se-
verity, but all exhibited at least subclinical signs of both skeletal muscle and cardiac disease. All
identiﬁed mutations lead to a partial or complete loss of function of BVES through nonsense-
mediated decay or through functional changes to the POPDC1 protein.
Conclusions
We report the identiﬁcation of homozygous LOF mutations in BVES, causal in a young adult-
onset myopathy with concomitant cardiac conduction disorders in the absence of structural
heart disease. These ﬁndings underline the role of POPDC1, and by extension, other members
of this protein family, in striated muscle physiology and disease. This disorder appears to have
a low prevalence, although it is probably underdiagnosed because of its striking phenotypic
variability and often subtle yet clinically relevant manifestations, particularly concerning the
cardiac conduction abnormalities.
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†These authors contributed equally to the manuscript as last authors.
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Limb-girdle muscular dystrophies (LGMDs) comprise
a phenotypically and genetically heterogeneous group of
autosomally inherited myopathies characterized by pro-
gressive proximal muscle weakness.1 Cardiac involvement is
common in LGMDs,2 and practice guidelines recommend
referring patients for cardiac assessment.3 Hereditary car-
diac conduction disorders without structural cardiac disease
are rare, but an increasing number of culprit genes are being
identiﬁed.4
Previously, a homozygous missense mutation (p.Ser201-
Phe) in the blood vessel epicardial substance (BVES) gene
has been identiﬁed in 3 individuals from a single family, the
eldest presenting with an overt LGMD phenotype and all 3
showing elevated creatine kinase (CK) levels and a second-
degree atrioventricular (AV) block.5 The disease was orig-
inally classiﬁed as LGMD2X (OMIM #616812). BVES
encodes for a 360 amino acid protein also known as
POPDC1, part of the Popeye domain containing (POPDC)
family of proteins, which are cyclic 39,59-adenosine mono-
phosphate (cAMP)-binding transmembrane proteins that
are abundantly expressed in striated muscle.6 In patients’
muscle, a marked reduction was observed in the membrane
localization of POPDC1 and POPDC2.5 In zebraﬁsh popdc1
morphants and popdc1p.Ser191Phe knock-in (KI) mutants,
skeletal muscle abnormalities and AV conduction blocks
have been noted.5 In addition, previously reported homo-
zygous Popdc1 null mutant mice showed delayed skeletal
muscle regeneration and an age-dependent stress-induced
sinus node dysfunction (SND).7,8
Here, we present 4 individuals from 3 families harboring
homozygous loss-of-function (LOF) mutations in BVES. We
show that the skeletal muscle and cardiac involvement
resulting from these BVES mutations is highly variable and
emphasizes the relevance of BVES mutations with regard to
hereditary cardiac conduction disorders.
Methods
Standard protocol approvals, registrations,
and patient consents
Ethical approval was granted by the relevant local ethical
committees of the participating centers. All patients provided
their written consent for participation in the study.
Patients and clinical evaluation
We studied 4 patients harboring rare variants in BVES,
identiﬁed by whole-exome sequencing (WES) of a cohort of
1929 unsolved cases with limb-girdle muscular weakness and/
or an elevated CK level, established through an international
collaboration between diﬀerent clinical and genetic centers:
the MYO-SEQ project, the Myocapture project, and the
Center for Medical Genetics of the Ghent University Hos-
pital. Patients 1 and 2 (family A) are siblings of consanguin-
eous parents (ﬁgure 1). Patient 3 (family B) and patient 4
(family C) are isolated cases, with the maternal grandfather
and paternal grandmother of patient 4 being ﬁrst cousins.
Medical history taking and physical examination were focused
on neuromuscular and cardiac symptoms and signs. Muscle
Figure 1 Segregation analysis of the 3 identified BVES mutations
Pedigrees of families A, B, and C are shown. Unaffected family members for whom DNA was available for segregation analysis of the BVES variants in the
respective families, I-1, II-1, II-2, III-1, III-2, III-3, and III-4, were heterozygous for the respective variants.
Glossary
AV = atrioventricular; CADD = Combined Annotation-Dependent Depletion; CK = creatine kinase; EPS = electrophysiology
study; EPS = electrophysiology study; ExAC = Exome Aggregation Consortium; IHC = immunohistochemical; KI = knock-in;
LGMD = limb-girdle muscular dystrophy; LOF = loss of function; NMD = nonsense-mediated mRNA decay; PCCD =
progressive cardiac conduction disorder; SND = sinus node dysfunction; WES = whole-exome sequencing.
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strength was evaluated according to the Medical Research
Council scale. Cardiac function was assessed by ECG, Holter
monitoring, and echocardiography in all patients. In addition,
arm ergometer stress testing was performed in patient 3 and
bicycle ergometer stress testing and a cardiac electrophysiol-
ogy study (EPS) in patient 2.
Muscle MRI
Muscle MRI studies were performed for patients 1, 2, and 3
on 1.5-T MRI platforms at the respective centers. Cross
sections at the pelvic, thigh, and calf levels were assessed on
axial T1-weighted images to evaluate patterns of muscle in-
volvement. Fatty replacement of muscle was graded according
to the Mercuri scale.9
Analysis of WES data
For family A, WES was performed by the CNRGH on DNA
samples from patients 1 and 2 and their mother. Variants were
annotated and ﬁltered using an in-house-developed software
system (PolyWeb).10 WES data of patient 3 were processed by
the Genomics Platform at the Broad InstituteMIT andHarvard
(Boston, MA) and analyzed by the team at the John Walton
Muscular Dystrophy Research Centre, Newcastle University, as
described previously.11 For patient 4,WESwas performed using
the SureSelect XT Human All Exon V6 enrichment kit (Agilent
Technologies), followed by paired-end sequencing (2 × 150 bp)
on the HiSeq3000 sequencer (Illumina). Reads were mapped,
and variants were called and annotated with the BCBio pipeline.
BVES (reference sequence: NM_001199563) was analyzed for
biologically relevant variants. Population frequencies were es-
timated using Exome Aggregation Consortium (ExAC),12 last
accessed in August 2018.MutationTaster213 and the Combined
Annotation Dependent Depletion (CADD)14 tool (version
v1.3) were used as in silico prediction algorithms to predict
the pathogenicity of the identiﬁed variants. Variants with
CADD scores >20 represent the 1% highest ranked variants
genome wide with regard to potential deleteriousness. In
silico splice site predictions were obtained using Alamut
Batch Software v.2.8 (Interactive Biosoftware). Variants
were validated by Sanger sequencing, and segregation
studies were performed with available DNA samples.
Muscle biopsies
Muscle biopsies of quadriceps or deltoid muscle were
obtained for patients 2, 3, and 4 and analyzed following
standard histologic and immunohistochemical (IHC) proce-
dures. Standard IHC stainings, including those for dystrophin,
α-, β-, and γ-sarcoglycans, α- and β-dystroglycan, caveolin 3,
and telethonin, were evaluated. In addition, IHC stainings
were performed for POPDC1 and POPDC2. Frozen 10-μm
sections of skeletal muscle biopsies of patients and 2 controls
were mounted on Superfrost Plus glass slides (Thermo Fisher
Scientiﬁc) and used for IHC using the following primary
antibodies as described5: anti-POPDC1 (HPA014788, Sigma-
Aldrich) and anti-POPDC2 (HPA024255, Sigma-Aldrich),
combined with anti-α-sarcoglycan (SGCA) (NCL-a-sarc,
Leica), for membrane counterstaining. The following sec-
ondary antibodies were used for detection of the signal: Alexa
Fluor 488–conjugated goat anti-rabbit (A11034, Life Tech-
nologies) and CY3labeled goat antimouse (115-166-071,
Jackson ImmunoResearch).
Microscopy and image analysis
Images were acquired with a Zeiss LSM700 laser scanning
confocal microscope using a 20×/0.8 Plan Apochromat ob-
jective. To avoid crosstalk between ﬂuorescence channels,
line-by-line sequential scanning was used. All images (16-bit,
512 × 512 pixels, 417 nm × 417 nm per pixel) were taken with
identical excitation and detection settings to allow compari-
son of ﬂuorescence intensities. For each sample, 5 images
were acquired at random positions. Intensities at the sarco-
lemma were quantiﬁed using the Fiji distribution of
ImageJ.15,16 Raw image ﬁles (LSM5) were loaded in Fiji, and
background intensity levels were corrected by subtracting the
mean intensity of the Gaussian blurred image (sigma = 20
pixels) from the original image. On each image, 6 random
membrane segments were delineated (average line length
per segment >50 μm) using the segmented line tool on the
sarcolemma channel and were stored as ImageJ ROI ﬁles.
Intensities in both channels (POPDC1/POPDC2 and
SGCA) were quantiﬁed as mean intensities of these lines,
set at a line width of 5 pixels (2 μm). The analysis pro-
cedure was used as an ImageJ macro, measuring all images
in batch.
mRNA studies
Total RNA was extracted from muscle biopsies (controls and
patients) using standard methods (TRIzol). First-strand
cDNA was synthesized using the SuperScript III First-
Strand Synthesis System (Invitrogen–Thermo Fisher Scien-
tiﬁc) with Oligo-dTs. The obtained cDNA was used for
Sanger sequencing and quantitative PCR (qPCR) experi-
ments with SYBR green I dye incorporation (LightCycler 480
System; Roche, Basel, Switzerland). The average Ct value
obtained with multiple BVES primers (ﬁgure 2A) was nor-
malized against the housekeeping gene RPLP0; then, fold
changes in mRNA levels were calculated relative to the con-
trol sample.
Experiments were performed in triplicate. All primer
sequences are available upon request.
Data analysis was performed with qBase + (Version 3.1;
Biogazelle, Zwijnaarde, Belgium). Data are presented using
GraphPad Prism (GraphPad Software, La Jolla, CA) as mean
values with standard error of the mean. Data were analyzed
using the unpaired t test. p < 0.05 was considered statistically
signiﬁcant.
Data availability statement
Anonymized data will be shared by request from any qualiﬁed
investigator, only for purposes of replicating procedures and
results.
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Results
Clinical findings and case descriptions
A summarized overview of the highly variable clinical symp-
toms is provided in table 1.
Patients 1 and 2 are aﬀected siblings, among 5, of consan-
guineous parents (ﬁrst cousins). Patient 1, a 41-year-old
woman, manifested complaints of exercise-induced myalgia
and fatigue of the lower limb muscles and breathlessness from
age 27 years. No further skeletal muscle signs or symptoms
were noted, and clinical neurologic examination was normal.
CK levels, repeatedly measured at that time, were elevated in
the range of 13003661 IU/L. EMG was normal, and cardiac
assessment revealed a ﬁrst-degree AV block in the absence of
structural cardiac disease on echocardiography. Muscle symp-
toms and cardiac function remained stable during follow-up.
Patient 2, a currently 37-year-old man, was ﬁrst investigated at
age 19 years, presenting with presyncopal episodes and palpi-
tations. During cardiac workup, a ﬁrst-degree AV block and
a transient second-degree Mobitz type 1 AV block were noted
on ECG and Holter monitoring, with an echocardiography
showing no structural abnormalities. There were no symptoms
suggestive of neuromuscular disease, and clinical examination at
age 20 years was normal. However, highCK levels (1,074–3,600
IU/L) were measured repeatedly, EMG disclosed myopathic
abnormalities, and muscle biopsy showed mild dystrophic
changes with normal routine IHC and Western blot studies.
Intercurrently, the patient manifested a symptomatic S1 radi-
culopathy on the right side at age 22 years, with residual
weakness and atrophy of the right gastrocnemius and soleus
muscles. An EPS at age 27 years conﬁrmed an AV nodal block,
with a normal His-ventricular interval and without SND or
ventricular hyperexcitability. During follow-up, this patient
manifested multiple presyncopal episodes, and the cardiac
conduction abnormalities progressed toward a second-degree
Mobitz type 2 AV block combined with an incomplete right
bundle branch block. A new EPS at age 29 years revealed
a combined AV nodal and infrahissian block (His-ventricular
interval ranging 55–80 ms), again without SND or hyperexcit-
ability. Pacemaker implantation was advised but refused by the
patient. Bicycle ergometer testing performed at age 35 years
showed a second-degree Mobitz type 2 AV block during
Figure 2 BVES gene structure and mRNA analysis
(A) BVES mRNA transcript variant C (NM_
001199563) contains 8 exons, of which 7 coding.
Transcript length is 5,567 base pairs. Untranslated
regions are filled in grey, translated in black. The
location of the 3 identified variants is marked with
an arrow, position of the amplified fragments for
quantitative and quantitative PCR experiments
with dashed lines. (B) Qualitative PCR: agarose gel
of PCR products (amplicons A, B, and C) amplified
from cDNA from control (C1) and patient 2 (P2).
For every amplicon, the 2 lanes on the right con-
tain mRNA without reverse transcriptase and
H2O, respectively. (C and D) BVES quantitative
mRNA analysis for amplicons A and C, respectively.
BVESmRNA levelswere first normalized internally to
RPLP0 mRNA levels; subsequently, BVES mRNA lev-
els of the patients were normalized (as a percent-
age) to the mean of the 2 controls. For both
ampliconsAandC, there isa significant difference in
mRNA levels between both controls and patients 2
and 3, respectively, which is not the case for patient
4. Error bars: standard error of themean (SEM). *p <
0.05, **p < 0.01, using the unpaired t test. bp = base
pair; Ex = exon.
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recovery. Apart from right S1 radiculopathy sequelae, no addi-
tional muscle weakness or wasting was noted during follow-up,
but CK levels stayed consistently elevated (maximal 5,500 IU/
L). Patient 3, a 65-year-old woman, developed slowly
progressive proximal weakness in the lower limbs in her mid-
thirties. Being very athletic up to that point, she noticed diﬃ-
culties in walking uphill and climbing stairs. A few years later, she
manifested slowly progressive proximal weakness in the upper
limbs too.When she was referred for neuromuscular workup for
the ﬁrst time at age 43 years, she climbed stairs on her hands and
feet. Clinical neurologic examination at that time conﬁrmed
proximal weakness in the lower limbs, as well as weakness of the
anterior tibial muscles. Scapular winging was found. The CK
level was 1,161 IU/L, and EMG revealed myopathic changes.
Over the following years, the muscle weakness was slowly
progressive, leading to loss of ambulation. Thorough cardiac
workup revealed a ﬁrst-degree AV block at night and a border-
line ﬁrst-degree AV block during exercise. Furthermore, no
increase in the heart rate (85/min during the whole test) was
observed during arm ergometer testing, halted because of ex-
haustion at 50 W. Both parents were deceased, and no neuro-
muscular or cardiac problems were reported. Of 5 siblings, 1 was
deceased, and none reported muscle or cardiac symptoms. One
sister agreed to be formally examined, and clinical examination
was unremarkable.
Patient 4, a currently 44-year-old man, reported mild myalgia
of the calves at age 39 years, 6 months after starting ﬁbrate
therapy for hypertriglyceridemia. A CK value of 8,000 IU/L
was measured, and he was referred to a cardiologist. The ﬁbrate
therapy was interrupted, muscle complaints diminished, and
control CK values averaged around 3,500–4,000 U/L. Initial
cardiac workup, including ECG, echocardiography, and Holter
monitoring, yielded normal results. The cardiologist referred the
patient for neuromuscular workup. By that time, muscle com-
plaints had resolved. Amyopathic recruitment pattern was noted
Table 1 Phenotypic information for the patients harboring homozygous mutations in BVES
Patient 1 Patient 2 Patient 3 Patient 4
Sex Female Male Female Male
Ethnicity North African North African Caucasian (Belgium) Caucasian (Belgium)
BVES variant, cDNA position c.816+2T>C c.816+2T>C c.262C>T c.1A>G
Age at onset, y 27 19 35 39
Presenting symptoms Exercise intolerance Palpitations, faintness,
and elevated CK
Proximal weakness LL Myalgia and high CK
Age at the last examination, y 41 37 65 44
Weakness
Proximal UL No No Yes No
Proximal LL No No Yes No
Distal UL No No Yes No
Distal LL No No Yes No
Other No Right calf muscles Periscapular No
Ambulation status Ambulatory Ambulatory Wheelchair use Ambulatory
Serum CK (IU/L) 1,300–3,661 1,074–5,500 1918 3,500–4,000
EMG (age, y) Normal (28) Myopathic (30) Myopathic (45) Myopathic (43)
Resting ECG First-degree AV block First-degree AV block Normal Normal
Echocardiography Normal Normal Aortic valve stenosis Normal
Holter monitoring First-degree AV block Second-degree AV block
(Mobitz type 2), iRBBB
Nocturnal first-degree AV
block
Nocturnal second-degree
AV block (Mobitz type 2)
Bicycle/arm ergometer stress testing NA Bicycle ergometer: Mobitz
type 2 second-degree AV
block during recovery
Arm ergometer: no
increase in the heart rate
during the test; borderline
first-degree AV block
NA
Biopsy (age, y) NA Myopathic (21) Myopathic (45) Myopathic (43)
Biopsied muscle NA Left deltoid Quadriceps Quadriceps
Abbreviations: CK = creatine kinase; UL = upper limb; LL = lower limb; AV = atrioventricular; iRBBB = incomplete right bundle branch block; NA = not assessed.
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on EMG though, as well as nonspeciﬁc myopathic features on
muscle biopsy. Clinical examination of 2 brothers, a 7-year-old
son, and a 5-year-old daughter was unremarkable. For the
parents and the 2 brothers, a normal CK value was measured.
Clinically, the patient remained stable during 5 years of follow-
up. Cardiac workupwas, however, repeated and revealed a ﬁrst-
degree AV block and a nocturnal second-degree Mobitz type 2
AV block. None of the patients presented with contractures,
rigid spine, clinical myotonia, or myotonic discharges on EMG.
Muscle imaging
MuscleMRI studies of patients 1, 2, and 3 are shown in ﬁgure 3.
For patient 1, muscle MRI performed at age 28 years and
repeated at age 39 years did not reveal any selective muscle
involvement. For patient 2, initial CT imaging of muscle at age
20 years was normal. At age 30 years, muscle MRI showed
moderate fatty replacement and atrophy of the right gastroc-
nemius, soleus, and biceps femoris muscles, visualizing the
clinically evident residual atrophy and weakness due to the S1
radiculopathy. Additional muscle MRI studies at age 35 years
conﬁrmed these ﬁndings.
Muscle MRI of patient 3, showing the most severe skeletal
muscle phenotype, revealed a pattern of selective muscle in-
volvement with preferential aﬀection of the posterior thigh
compartment. In addition, an asymmetric moderate in-
volvement of the left lateral vastus and relative sparing of distal
leg muscles were observed.
Genetic findings
We identiﬁed 3 diﬀerent homozygous variants in BVES in 3
families (table 2). Variants were absent from the ExAC control
database, and in silico prediction algorithms were in favor of
pathogenicity. Segregation analyses were performed with
available DNA samples (ﬁgure 1). Only aﬀected individuals
harbored the variant in the homozygous state. The c.816+2-
T>C variant in intron 6 of BVES aﬀects the highly conserved
canonical T of the splice donor site and is predicted to cause
skipping of exon 6 and the loss of 56 amino acids (p.Val217_
Lys272del) within the Popeye domain of BVES. Two potential
cryptic splice sites could be activated alternatively: in intron 6
(c.816+46, p.Lys272fs4*) or within exon 6 (c.749*,
p.Arg250Argfs20*). The c.262C>T variant (rs796206315)
introduces a premature stop codon at amino acid position 88,
located in the second transmembrane domain of this short
protein. According to the MutationTaster2 algorithm,13 the
c.1A>G variant is predicted to result in a loss of the initiating
methionine (cDNA position 218) and potential activation of
a downstream translation initiation site at cDNA position 354,
resulting in a new reading frame with insertion of a premature
stop codon at amino acid position 2. As this potential alter-
native initiation site is not embedded in a strong Kozak se-
quence, other initiation sites might be activated at cDNA
position 423 or 431. In both cases, this would lead to an in-
frame deletion of 66 or 72 amino acids, respectively. Activation
of diﬀerent alternative start codons located more downstream
could, however, also result in a shift of the reading frame with
insertion of a premature stop codon.
Molecular consequences at the mRNA level
To provide direct evidence for the predicted alterations at the
transcript level, Sanger sequencing and qPCR experiments
were performed with mRNA extracted from muscle biopsies
of patients 2, 3, and 4. PCR products of BVES cDNA
Figure 3 Muscle MRI findings in 3 patients harboring homozygous mutations in BVES
Axial T1-weighted images are shown for patients
1, 2, and 3, performed at ages 39, 35, and 56
years, respectively.
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amplicons A, B, and C (ﬁgure 2A) could all be sequenced
(data not shown), and all variants were conﬁrmed at the
cDNA level. Gel electrophoresis of the amplicon B encom-
passing exon 4 up to and including 8 revealed a shorter product
for patient 2, sized approximately 350 base pairs (bp) instead of
the expected size of 507 bp (ﬁgure 2B). The sequencing of this
fragment conﬁrmed that exon 6 (168 bp long) was indeed
spliced out. Nevertheless, fragment C could be ampliﬁed for
patient 2, although the forward primer is located in exon 6.
qPCR data, however, showed that these mRNA levels for
amplicon C are close to 0 compared with the controls, in-
dicating that the absolute level of mutant mRNA in which exon
6 is not skipped is extremely low. Furthermore, mRNA levels
for amplicon A are markedly decreased as well, indicating
nonsense-mediated mRNA decay (NMD) of the mutant
transcript in any case. For patient 3, qPCR for amplicons A and
C revealed a marked decrease in BVES mRNA relative to the
controls (ﬁgure 2, C and D). For patient 4, BVESmRNA levels
are similar to these in the controls.
Reduction in membrane localization of
POPDC1 and POPDC2
Nonspeciﬁc myopathic features such as increased ﬁber size
variation were noted onmuscle biopsies of patients 2, 3, and 4.
In addition, for patient 2, a few necrotic ﬁbers were observed.
Standard IHC stainings were normal.
For the previously described patients harboring the
p.Ser201Phe in BVES in homozygosity, defective POPDC1
membrane traﬃcking was reported to result in strongly re-
duced membrane localization of POPDC1 and POPDC2.5
To examine POPDC1 and POPDC2 at the plasma mem-
brane, we performed IHC stainings in patient and control
muscle samples. Both POPDC1 and POPDC2 were abun-
dantly present at the plasma membrane of control skeletal
muscle. In all patient samples, however, both POPDC1 and
POPDC2 were drastically diminished at the sarcolemma
(ﬁgure 4, A-D). Levels of SGCA, used as a control marker for
sarcolemmal proteins, remained normal in the patient sam-
ples with similar staining patterns and intensities as for control
samples. These results conﬁrm that the predicted LOF
mutations in BVES indeed lead to a loss of membrane local-
ization and consequently the main function of POPDC1 and
POPDC2 in patient muscle.
Discussion
In the present study, we identiﬁed 3 diﬀerent new homozy-
gous LOF mutations in BVES in 4 individuals from 3 families,
showing early adult-onset skeletal muscle and cardiac con-
duction abnormalities of varying nature and severity.
The presenting symptoms vary between individuals, with
patient 2 presenting with cardiac symptoms due to an AV
conduction defect within the second decade and patients 1, 3
and 4 with skeletal muscle symptoms or signs. Only patient 3
showed progressive proximalmuscle weakness, whereas patient
1 had symptoms of exercise intolerance, and patient 4 had
permanently high CK levels (>3,500 IU/L after interruption of
ﬁbrate therapy) with transient complaints of myalgia. During
follow-up, all patients appeared to have at least subclinical signs
of both skeletal muscle and cardiac involvement. In patient 2
with a predominant cardiac phenotype, a chronically elevated
CK level (>1,000 U/L) was noted repeatedly, as well as
myopathic features on EMG and muscle biopsy. In patients 1,
3, and 4, initially showing a predominant skeletal muscle phe-
notype of variable severity, a progressive cardiac conduction
disorder (PCCD) became apparent during follow-up.
Intrafamilial variability of the phenotype linked to mutations
in BVES has already been shown in the originally reported
consanguineous family in which a pseudodominant in-
heritance pattern of the p.Ser201Phe variant was described5:
the grandfather presented with an LGMD phenotype at age
40 years, complicated by a symptomatic second-degree AV
block at age 59 years requiring pacemaker implantation, and
the grandsons with symptomatic second-degree AV block,
respectively, at age 17 years and 12 years. Cardiac conduction
disorders seemed to be conﬁned to the AV node.5 However,
for patient 2, deﬁnite His-bundle involvement was shown on
Table 2 BVES mutations identified in the present study
Patient
Variant location (hg19)
Protein
change Genotype Variant
Predicted deleteriousness
ExAC allele
frequency
Genomic (chr.
6) Coding MutationTaster2
CADD
score
1 105564574A>G c.816+2T>C p.? Hom. Splice
donor
No data No data 0
2 105564574A>G c.816+2T>C p.? Hom. Splice
donor
No data No data 0
3 105577343G>A c.262C>T p.Arg88Ter Hom. Stop
gained
Disease causing 39 0
4 105581452T>C c.1A>G p.? Hom. Start lost Disease causing 24.1 0
Abbreviations: Hom. = homozygous; CADD = Combined Annotation-Dependent Depletion; start lost = variant in the start codon; ExAC = Exome Aggregation
Consortium.
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an EPS at age 29 years. Although not fulﬁlling the exact cri-
teria of chronotropic incompetence,17 the results of the arm
ergometer testing in patient 3 are strongly indicative of SND.
Because of lower limb weakness, only less standardized arm
ergometer testing could be performed for this wheelchair-
using patient. During an incremental dynamic exercise test,
work load was limited to 50W, mainly because of weakness of
the biceps muscles.
Similarly, heterogeneity was observed on muscle imaging
studies. For patient 3, a pattern of selective muscle in-
volvement was shown, with muscles of the posterior com-
partment of the thighs being most severely involved. Muscle
MRI studies of patient 1 yielded normal results. The selective
unilateral atrophy and fatty replacement of soleus, gastroc-
nemius, and biceps femoris muscles in patient 2 may be due to
S1 radiculopathy.
Figure 4 Reduction of POPDC1 and PODPC2 at the sarcolemma inmuscle of patients harboring homozygousmutations in
BVES
(A and B) Representative muscle sections of patients and controls immunostained for POPDC1 and POPDC2, respectively, and α-sarcoglycan (SGCA) as
sarcolemmalmarker. All imageswere acquiredwith identical settings and are displayed in the figure with identical intensity scaling for each channel. Scale bar =
50 μm. (C and D) Fluorescence intensities measured at the sarcolemma (n = 30 sarcolemmal segments at random positions on the section). AU = arbitrary unit.
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As we identiﬁed additional unrelated families with a BVES-
related myopathy, we propose that this disorder should be
classiﬁed as “LGMD R25 BVES-related” according to the
recently published novel European Neuromuscular Centre
classiﬁcation of LGMDs. “LGMD2X” was excluded from the
LGMD nomenclature, based on the criterion that the con-
dition must be described in at least 2 unrelated families with
aﬀected individuals.18 All other criteria of the novel deﬁnition
of an “LGMD” are fulﬁlled too. Each patient achieved in-
dependent walking and has an elevated CK activity. De-
generative changes on muscle imaging are clearly shown on
muscle MRI of patient 3 of the current study and dystrophic
changes on histology, noted for the same patient, had already
been described for the eldest patient of the originally reported
family too.5,18 IHC experiments revealed a pattern of con-
sistent reduction of POPDC1 and POPDC2 at the sarco-
lemma, similar to the pattern described in muscle of patients
harboring the homozygous p.Ser201Phe missense mutation
and the popdc1p.Ser191Phe KI zebraﬁsh.5 Of note, for patient 3,
harboring the homozygous p.Arg88Ter variant, no antibody
targeting an epitope at the N-terminal side of the premature
stop codon was available. In addition, mRNA studies are
supportive of a LOF mechanism at the mRNA level for the
BVES variants in patients 2 and 3, most likely due to NMD.
For patient 2, qualitative and quantitative PCR data illustrate
that diﬀerent splice variants are transcribed, though ultimately
leading to signiﬁcantly decreased BVES mRNA levels. The
low level of remaining mRNA probably mainly consists of
mRNA with in-frame skipping of exon 6, encoding for 56
amino acids (p.Val217_Lys272del), which are part of the
Popeye domain, the crucial functional domain of the protein.
For patient 4, BVESmRNA levels were similar to these in the
controls. Apparently, the mutant mRNA is not targeted by
NMD, yet a nonfunctional protein is translated, which is not
recognized by the anti-POPDC1 antibody, raised against the
C-terminal part of the POPDC1 protein. In case of an in-
frame deletion of 66 or 72 amino acids at the N-terminal end
of the protein, the antibody should still recognize this trun-
cated POPDC1 protein. This observation most likely
implies that there is a shift of the reading frame, with
a premature stop codon less than 55 nucleotides upstream
of the last exon-exon border. In that case, NMD will be
skipped and a protein with a diﬀerent amino acid sequence
is formed, not recognized by the anti-POPDC1 antibody.
All mutations identiﬁed lead to a partial or complete loss
of function of BVES through NMD or through functional
changes to the POPDC1 protein.
By identifying and elaborating on LOFmutations in BVES, we
expand the genetic spectrum of the disorder and provide
pathomechanistic insights in the disorder. Only the
p.Ser201Phe missense mutation had been previously identi-
ﬁed in a single family. Identiﬁcation of patients harboring
LOF mutations in BVES could, however, be anticipated based
on functional studies in homozygous zebraﬁsh popdc1 mor-
phants and Popdc1 null mutant mice, showing a similar phe-
notype compared with the popdc1p.Ser191Phe KI zebraﬁsh.5,7,8
Of interest, the Popdc1 null mutant mice revealed an age-
dependent stress-induced SND with chronotropic in-
competence,8 a condition we also strongly suspect in patient
3. Further studies are needed to unveil the exact functional
consequences of the complete loss of function of the
POPDC1 protein in skeletal muscle and the heart. Crucially,
POPDC2 appears to be a direct interactor of POPDC1, and
aberrant traﬃcking of POPDC1 also impairs membrane
transport of POPDC2. Heteromeric complexes might be
formed, potentially explaining the secondary loss of mem-
brane localization of POPDC2, similarly shown for patients
harboring the p.Ser201Phe missense mutation.5 This appears
to be pathomechanistically relevant, as popdc2 zebraﬁsh
morphants show a severe muscular dystrophy phenotype and
cardiac abnormalities too.19
Our ﬁndings stress the importance of a thorough cardiac
workup in (unsolved) LGMD patients. Cardiac workup is
often focused on structural cardiac evaluation,3 but as in
myotonic dystrophy,2 extensive and repeated screening for
arrhythmias in the absence of structural heart disease is deﬁ-
nitely relevant in case of a BVES-related myopathy.
Furthermore, this study highlights the diagnostic diﬃculties
that can be faced in case of pauci- or asymptomatic hyper-
CKemia.20 We note chronically elevated CK values (>3 times
the upper limit of normal) in all patients. In the absence of
marked dystrophic features on muscle biopsy, this may be an
indication of membrane instability linked to the interaction of
POPDC1 with dystrophin, dysferlin, and caveolin 3.6,21 In
addition, ultrastructural analysis of muscle of the grandfather
of the p.Ser201Phe family revealed membrane dis-
continuities.5 When further neuromuscular workup is advised
in this clinical setting according to guidelines,20,22 cardiac
screening could be relevant too, regardless of the results of the
neuromuscular workup. The other way around, our ﬁndings
suggest that BVES should be included in a candidate gene list
for PCCDs presenting as primary electrical disease. The
search for culprit genes has long been complicated by the fact
that most cardiac conduction disorders are sporadic, as they
are highly prevalent and usually associated with diverse (ac-
quired) structural heart disease. Channelopathies are evi-
dently the predominant hereditary entities associated with
PCCD.4,23 Furthermore, a short clinical neuromuscular
evaluation, including CK measurement, could be of value
when a hereditary PCCD is suspected.
Identiﬁcation of LOF mutations in BVES underlines by ex-
tension the role of the POPDC protein family in striated
muscle physiology and disease.6 We present 4 individuals
from 3 families harboring homozygous LOF variants in BVES,
showing early adult-onset skeletal muscle and cardiac con-
duction abnormalities of varying nature and severity. Overall,
this recessive disorder linked to mutations in BVES appears to
have a low prevalence, but is probably underdiagnosed be-
cause of its striking phenotypic variability and often subtle yet
clinically relevant manifestations.
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